kabutan

CanBas Co.,Ltd.(4575) Summary

4575
TSE Growth
CanBas Co.,Ltd.
799
JPY
-15
(-1.84%)
Dec 5, 12:42 pm JST
5.15
USD
Dec 4, 10:42 pm EST
Result
PTS
outside of trading hours
800.6
Dec 5, 12:44 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.14
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
809 JPY 5.21 USD
Previous Close Dec 4
814 JPY 5.23 USD
High Dec 5, 9:08 am
816 JPY 5.25 USD
Low Dec 5, 10:44 am
794 JPY 5.12 USD
Volume
104,700
Trading Value
0.08B JPY 0.54M USD
VWAP
805.92 JPY 5.2 USD
Minimum Trading Value
79,900 JPY 515 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
364
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,309
1-Year High Aug 21, 2025
19,409
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 1,460,800
Nov 21, 2025 0 1,464,700
Nov 14, 2025 0 1,527,700
Nov 7, 2025 0 1,518,100
Oct 31, 2025 0 1,581,800
Company Profile
CanBas Co., Ltd. is a drug discovery venture specializing in anticancer drug development. Its primary source of income is research and development support funds. The company is actively seeking partnership opportunities.
Sector
Pharmaceuticals
CanBas Co., Ltd. is a drug discovery venture focusing on basic research, early clinical development, and late-stage clinical development of anticancer drugs. Leveraging its unique drug discovery approach, the company has a development pipeline consisting of multiple drug candidate compounds. CanBas utilizes external specialized institutions and a scientific advisory board, aiming for synergy by combining in-house development with strategic partnerships with pharmaceutical companies. The company's lead compound, CBP501, is currently undergoing Phase 2 clinical trials in combination with immune checkpoint inhibitor antibodies. CBS9106 has been licensed to a U.S. company and is progressing through clinical development. In addition to these, CanBas is conducting exploratory research on multiple novel candidate compounds. The company's immediate priorities are accelerating the development of CBP501 and maximizing its chances of success, while continuing basic research to deepen understanding of existing pipelines and generate next-generation pipelines. Continuous fundraising through direct financing is also positioned as one of the company's challenges and strategies to support these efforts.